What is it used for?
Ezharmia contains valemetostat, an EZH1/2 inhibitor. The Japanese review covers relapsed or refractory adult T-cell leukemia-lymphoma and the expanded indication of relapsed or refractory peripheral T-cell lymphoma. These diagnoses require specialist confirmation.Ezharmia contains valemetostat, an EZH1/2 inhibitor. The Japanese review covers relapsed or refractory adult T-cell leukemia-lymphoma and the expanded indication of relapsed or refractory peripheral T-cell lymphoma. These diagnoses require specialist confirmation.
Read the primary sourceThis source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.
Product details
- Active ingredient
- valemetostatvalemetostat
- Form and strength
- Oral tablets containing 50 mg or 100 mg valemetostat, supplied as the tosylate salt.Oral tablets containing 50 mg or 100 mg valemetostat, supplied as the tosylate salt.
- Manufacturer / applicant
- Daiichi Sankyo Company, LimitedDaiichi Sankyo Company, Limited
Oral tablets containing 50 mg or 100 mg valemetostat, supplied as the tosylate salt.Oral tablets containing 50 mg or 100 mg valemetostat, supplied as the tosylate salt.
Safety and clinical review
PMDA identifies suppression of blood-cell production, infections and secondary malignancy as important post-marketing safety topics.PMDA identifies suppression of blood-cell production, infections and secondary malignancy as important post-marketing safety topics.
- Blood-cell suppressionBlood-cell suppression
- InfectionsInfections
- Secondary malignancy monitoringSecondary malignancy monitoring
Ask your clinician to review the complete label, medical history, other medicines, allergies, pregnancy or breastfeeding and any required monitoring. Do not start, stop or change treatment from this page.
Read the primary sourcePrepare your enquiry
Include the brand or generic name, strength, dosage form, requested quantity and country where care is needed. You can attach a prescription when you continue.
Questions patients ask
What is EZHARMIA used for?
Ezharmia contains valemetostat, an EZH1/2 inhibitor. The Japanese review covers relapsed or refractory adult T-cell leukemia-lymphoma and the expanded indication of relapsed or refractory peripheral T-cell lymphoma. These diagnoses require specialist confirmation.Ezharmia contains valemetostat, an EZH1/2 inhibitor. The Japanese review covers relapsed or refractory adult T-cell leukemia-lymphoma and the expanded indication of relapsed or refractory peripheral T-cell lymphoma. These diagnoses require specialist confirmation.
This source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.
Which formulation of EZHARMIA should I ask about?
Oral tablets containing 50 mg or 100 mg valemetostat, supplied as the tosylate salt.Oral tablets containing 50 mg or 100 mg valemetostat, supplied as the tosylate salt.
Read the primary sourceWhat determines the price of EZHARMIA?
A current quote depends on the exact presentation, quantity, provider and access arrangements. A catalogue entry is not a stock or delivery promise. Medical charges are paid to the provider, separately from coordination fees.
What should I check before using EZHARMIA?
Ask your clinician to review the complete label, medical history, other medicines, allergies, pregnancy or breastfeeding and any required monitoring. Do not start, stop or change treatment from this page.
Sources and review scope
This source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.